bbn/illustration/Expert Says Molnupiravir, Expected to be a Covid-19 Drug
“It should also be noted that in April 2021 clinical trials of this drug molnupiravir in hospitalized patients were stopped, because it did not show good results in patients who had been admitted to the hospital,” said Professor Yoga in a statement to Suara.com, Wednesday ( 6/10/2021).
However, the drug produced by the pharmaceutical company Merck & Co was decided to continue the clinical trial process, but given to Covid-19 patients before being hospitalized.
“When it was decided in April that the research would be continued only on those who had not yet been admitted to the hospital, the results were only announced on October 1,” said Professor Yoga.
The health expert who is also the former Director of WHO Southeast Asia revealed that research results proved that the efficacy of the drug consistently worked against all corona viruses that had been found.
“The data in 40 percent of the sample that the efficacy of molnupiravir is consistent across the various variants found, namely Gamma, Delta, and Mu,” he said.